ADMA Biologics Q4 2023 Adj EPS $0.04 Beats $0.03 Estimate, Sales $73.90M Beat $72.15M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics reported Q4 2023 earnings of $0.04 per share, surpassing the consensus estimate of $0.03. Sales reached $73.90M, exceeding the $72.15M estimate and marking a 47.86% increase from the previous year.
February 28, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics exceeded Q4 2023 earnings and sales estimates, with a significant year-over-year sales increase.
Beating both earnings and sales estimates, especially with a substantial year-over-year sales growth, is likely to be viewed positively by investors. This outperformance could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100